GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shaanxi Kanghui Pharmaceutical Co 603139.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

28.76

-1.37%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Shaanxi Kanghui Pharmaceutical Co

Its shares trade on Shanghai under the ticker 603139.SS. It has been listed since 21 April 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥471.3m and a net loss of CN¥333.5m. At that date it held total assets of CN¥1.81bn and shareholders' equity of CN¥524.9m.

Shaanxi Kanghui Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of Chinese medicine. The company is headquartered in Xianyang, Shaanxi. The company went IPO on 2017-04-21. The firm's main products include Kun Fu Kang capsules (tablets), Fufang Shuanghua tablets, Xiaoyin granules, Fuguigutong capsules, Zhiyao Xiaoke capsules and Fufang Qingdai perfusates. The firm distributes its products just within China domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
21 Apr 2017
Employees
828
Website
sxkh.com ↗

Leadership

Pay as last reported

  • Mr. Yanling WangChairman of the Board, General Manager, since 2009CN¥490,900
  • Mr. Binze ZouChief Financial OfficerCN¥139,400
  • Ms. Jin YangExecutive Deputy General Manager, Director, since 2013CN¥409,800
  • Mr. Jingyi ZhaoDeputy General Manager, Director, since 2009CN¥248,000
  • Mr. Wenquan GuoDeputy General ManagerCN¥224,600
  • Ms. Juan DongSecretary of the BoardCN¥105,600
  • Mr. Jianping HouDirector
  • Mr. Jiang HuDirector
  • Mr. Junmin ZhangDirector
  • Mr. Jianwei DouIndependent DirectorCN¥71,900
  • Mr. Yuke KangIndependent DirectorCN¥71,900
  • Mr. Weitao YeIndependent DirectorCN¥71,900

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Xianyang, Shaanxi
  • Employs 828 full-time employees
  • Focuses on Chinese medicine research, development, and manufacturing

Weaknesses

  • Products distributed only within China domestic market
  • No international market presence mentioned
  • Limited product range described as main products only

Opportunities

  • Potential for expanding into international markets
  • Growth in Chinese medicine sector within China
  • Opportunities for product diversification

Threats

  • Dependence on domestic market for sales
  • Competition within the Chinese pharmaceutical industry
  • No mention of R&D investment or innovation strategies

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.